References
- Lethé B, Van den Eynde B, Van Pel A, Corradin G, Boon T. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol 1992; 22; 2283–8.
- Grohmann U, Bianchi R, Fioretti MC, et al. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol 1995; 25; 2797-2802.
- Bianchi R, Grohmann U, Belladonna ML, et al. IL-12 is both required and sufficient for initiating T-cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J Immunol 1996; 157; 1589-1597.
- Uyttenhove C, Maryansky J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 1983; 157; 1040-1052.
- Grohmann U, Bianchi R, Ayroldi E, et al. A tumor-asso-ciated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J Immunol 1997; 158; 3593–3602.